Pregabalin
Product Images NDC 71610-329

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 300 mg (71610 0328 30)

Pregabalin 300mg capsules label showing a 30-capsule package. The label includes storage instructions, manufacturer SC Teigen Pharmaceuticals Inc, and labeler Aphena Pharma Solutions - Tennessee, LLC. It has NDC number 71610-0328-30 and states RX only with a warning about potential habit forming.*

FDA Label Image

Bottle Label 100 mg (71610 0329 30)

Pregabalin 100mg capsules label from Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, use precautions, manufacturer information (Seidell Pharmaceuticals Inc), and details such as NDC code 71610-0329-30. The package contains 30 capsules, and the label notes the product is RX only with a warning about potential habit-forming properties.*

FDA Label Image

Bottle Label 200 mg (71610 0330 53)

Label for Pregabalin 200 mg capsules, containing 60 capsules per bottle. Manufactured by Sun Pharmaceutical Industries Ltd and packed by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label includes storage instructions, warnings, and barcodes.*

FDA Label Image

Bottle Label 225 mg (71610 0331 53)

Label for Pregabalin 225 mg capsules, containing 60 capsules. The label includes storage instructions to keep between 20-25°C and out of reach of children. Manufactured by SciEwen Pharmaceuticals Inc and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. The label includes a caution that the medication may be habit forming.*

FDA Label Image

Bottle Label 50 mg (71610 0332 30)

Pregabalin 50 mg capsules label by Aphena Pharma Solutions - Tennessee, LLC. The label includes product name, dosage strength (50 mg), quantity (30 capsules), storage instructions (store between 15-30°C), and manufacturer information (ScieGen Pharmaceuticals Inc). The label also highlights prescription status (RX Only) and warnings about habit-forming potential.*

FDA Label Image

Bottle Label 75 mg (71610 0333 30)

Label for Pregabalin 75 mg capsules, packaged in a bottle containing 30 capsules. The label indicates storage instructions at controlled room temperature and to keep out of reach of children. It also notes the product is prescription-only and manufactured by Scifeon Pharmaceuticals Inc, with repackaging by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Bottle Label 150 mg (71610 0334 30)

Pregabalin 150 mg capsules packaging label with NDC 71610-0334-30. The label shows 30 capsules, manufactured by SciEdGen Pharmaceuticals Inc, and distributed by Aphena Pharma Solutions - Tennessee, LLC. Storage instructions indicate to keep at controlled room temperature and out of reach of children. The label includes a warning that the drug may be habit forming and is marked RX Only.*

FDA Label Image

Bottle Label 25 mg (71610 0335 30)

Pregabalin 25 mg capsules packaging label showing a bottle containing 30 capsules. The label includes storage instructions to keep at controlled room temperature and in a tightly-closed, light-resistant container. The manufacturer is SciGen Pharmaceuticals Inc., and the labeler is Aphena Pharma Solutions - Tennessee, LLC, located in Cookeville, TN.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares different doses of Pregabalin (200 mg, 100 mg, 25 mg three times a day) and placebo, showing their relative effectiveness in pain improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day and placebo, showing higher percentages of patient improvement for Pregabalin across various thresholds of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting percent of patients improved against percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline, illustrating dose-dependent patient improvement.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved at different levels of percent improvement in pain from baseline. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo, with the vertical axis representing the percent of patients improved and the horizontal axis representing the percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows comparative trends of pain improvement among the three groups with labeled axes and vertical reference lines.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) at various dosages of Pregabalin versus placebo in two clinical studies labeled Study E1 and Study E3. Study E1 includes placebo and doses ranging from 50 mg/day to 600 mg/day, showing increasing responder rates up to 51%. Study E3 compares placebo, 300 mg/day (BID), and 600 mg/day (TID) with responder rates reaching 49%. An asterisk indicates statistical significance versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A scatter plot with dose in mg/day on the x-axis and seizure reduction as median percentage change from baseline on the y-axis. The graph compares seizure reduction across different studies and dosing schedules of Pregabalin, showing significant p-values for dose-related effects.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line chart showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Four curves represent different treatments: Pregabalin 800mg daily dose, 450mg daily dose, 300mg daily dose, and placebo. The graph compares patient response rates across these dosing groups.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The solid line represents Pregabalin, maintaining a higher percentage than the dashed line representing placebo throughout the duration.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to Week 12, labeled as BOCF. The graph shows two lines: one solid line representing Pregabalin and one dashed line representing Placebo, illustrating comparative effectiveness data for Pregabalin versus Placebo over time.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 16, showing data for Pregabalin and Placebo. The x-axis represents percent improved from baseline to week 16 BOCF, and the y-axis shows the percent of subjects improved. Pregabalin data is shown as a solid line and Placebo as a dashed line.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Illustration of a formula calculating creatinine clearance (CLcr), which incorporates age, weight, serum creatinine levels, and includes an adjustment factor for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of Pregabalin showing its molecular formula with specific stereochemistry, including an amino group and a carboxylic acid group attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.